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Objectives: To examine temporal changes of infective endocarditis (IE) incidence and 
epidemiology in North America.  
Patients and Methods: A systematic review was conducted at Mayo Clinic, Rochester. Ovid 
EBM Reviews™, Ovid Embase™, Ovid Medline™, Scopus™, and Web of Science™ were 
searched for studies published between January 1, 2000 and May 31, 2020. Four referees 
independently reviewed all studies, and those that reported a population-based incidence of 
IE in patients aged 18 years and older in North America were included.  
Results: Of 8,588 articles screened, 14 were included. Overall, IE incidence remained largely 
unchanged throughout the study period, except for two studies that demonstrated a rise in 
incidence after 2014. Five studies reported temporal trends of injection drug use (IDU) 
prevalence among IE patients with a notable increase in prevalence observed. Staphylococcus 
aureus was the most common pathogen in 7 of 9 studies that included microbiologic findings. 
In-patient mortality ranged from 3.7-14.4%, while the percentage of patients who underwent 
surgery ranged from 6.4-16.0%. 
Conclusion: Overall incidence of IE has remained stable among the 14 population-based 
investigations in North America identified in our systematic review. Standardization of study 
design for future population-based investigations have been highlighted for use in subsequent 
systematic reviews of IE. 
































































































Among the variety of diseases involving the cardiovascular system, infective 
endocarditis (IE) is less commonly seen. Nevertheless, due to the high (up to ~40%) one-year 
mortality rate, frequent need for surgical intervention and common requirement of prolonged 
hospital stays, the syndrome deserves close surveillance. Moreover, the ever-changing 
epidemiology of IE coupled with an increasing incidence demonstrated in some 
investigations warrants a contemporary review.  
The expected IE patient “phenotype” of older, particularly male, patients 
predominates and has for decades. Factors responsible for this clinical profile are multiple 
and include implantation of an ever-increasing array of cardiovascular devices with the bulk 
of these devices placed in older patients, often with comorbid conditions. Degenerative 
cardiac valve disease is also important in IE epidemiology among older patients. The survival 
of patients with congenital heart disease into adulthood has also influenced the epidemiology 
of IE where a broader age range of adult patients has been observed. In contrast, the almost 
complete elimination of rheumatic carditis in North American has impacted the prevalence of 
IE among younger adults in North America.  
Injection drug use (IDU) as a complication of the ongoing opioid epidemic has 
changed the epidemiologic landscape of many regions of North America. Unlike IE seen 
decades ago, more rural areas have described escalating rates of IE among younger, 
otherwise healthy people who inject drugs (PWID), with a predominance of infection due to 
Staphylococcus aureus, one of the most virulent pathogens that causes IE. Moreover, IDU-
related IE has not been limited to right-sided IE as both left-sided and bilateral involvement 
have often been seen with increased morbidity and mortality. Despite the prevalence of 





























































































been impacted, in part related to the referral of IE patients for management expertise. For 
example, the prevalence of PWID in adult patients with IE seen recently in Boston, 
Massachusetts and Lexington, Kentucky has reached 46% and 73%, respectively. 
Marked restrictions in the use of antibiotic prophylaxis (AP) introduced by the 2007 
American Heart Association (AHA) guidelines, which have been adopted by both Canada 
and the United States, represent another factor that could impact the epidemiology, and to a 
lesser extent, the incidence of IE in North America. These restrictions accounted for ~90% 
reduction in AP for invasive dental procedures and prompted concerns that more cases of IE 
due to viridans group streptococci (VGS) would occur. Ongoing investigations continue to 
evaluate for this possibility, but based on work published to date, a clear determination of an 
increase in VGS IE following introduction of these guidelines is lacking, in part due to the 
lack of microbiologic data reported in these publications. Furthermore, no specific 
International Classification of Diseases (ICD) codes exist to date, remarkably, for VGS. The 
updated (2021) AHA Statement largely reflects the changes in the 2007 version but was 
revised to focus only on invasive dental procedures and IE due to VGS. In response to the 
many factors outlined above, we conducted a systematic review of population-based studies 
that evaluated temporal trends of IE epidemiology in the adult population of North America 
from 2000 onwards.  
METHODS 
 A literature search was performed with a focus on the incidence and epidemiology of 
IE. It was conducted in June 2020 in Ovid EBM Reviews™, Ovid Embase™, Ovid 
Medline™, Scopus™, and Web of Science™ for papers published between January 1, 2000 
and May 31, 2020. The search was limited to the English language. Search strategies are 





























































































were deleted. Two reviewers (K.M.T and L.M.B) performed the literature review and any 
disagreements were solved by discussion with two additional reviewers (M.J.D. and D.C.D). 
Corresponding authors of studies were contacted via email in cases where queries existed.  
Patient Consent Statement  
The study was exempt from patient consent, as it does not include factors 
necessitating patient consent. The Mayo Clinic Institutional Review Board approved the 
study 
Inclusion and exclusion criteria 
All studies which provided information on population-based trends of IE in the adult 
(≥ 18 years) population of North America from 2000 onwards were included in the review. 
Single-center and multi-center studies, clinical trials, case reports, conference abstracts, 
systematic reviews and animal studies were excluded, as were investigations that reported 
crude incidence without a population-based estimate. In addition, studies that determined IE 
incidence that was specific to infecting pathogens or unique patient populations (e.g. HIV-
infected, congenital heart disease) were also excluded. Details of the search strategy are 
provided in the Supplement. 
Data extraction 
Data that described authors, publication year, study location, population covered, 
average age, incidence rate, IE microbiology, mortality, IDU, and cases requiring surgery as 






























































































Study definition and outcomes 
The primary outcome was incidence of IE, while secondary outcomes were 
prevalence of PWID among IE patients, pathogen prevalence, proportion of patients that 
required valvular surgery and mortality (stratified as inpatient, six-month and one-year 
mortality). All included studies defined IE using primary or secondary diagnosis based on 
International Classification of Diseases ninth revision (ICD 9) and tenth revision (ICD 10). 
Studies that defined IE using either Duke criteria or modified Duke criteria as possible or 
definite IE were also included.  
Risk of bias 
Two reviewers (K.M.T and W.T.) independently rated the methodologic quality of 
each study. We assessed the quality of each population-based survey based on four key 
features: adequacy of population definition, sampling techniques, disease definition, and 
completeness of case ascertainment, as summarized in Table 2. We deemed the population 
definition to be inadequate if residency status population of interest was not confirmed. 
Optimal sampling techniques include complete enumeration or random sampling techniques. 
Adequacy of case ascertainment was assessed based on case-finding procedures, inclusion of 
postmortem diagnoses, and number of hospitals serving the population under study that 
participated in the study. Author statements about shortfall in case ascertainment were also 
considered an indication of inadequate case ascertainment. Based on these criteria, we 
excluded studies that had considerable shortfalls in case ascertainment and/or lacked a case 
definition. Reviewer disagreements were resolved by consensus after review of the article. A 





























































































The study was registered with the international prospective register of systematic 
reviews (PROSPERO), which is an international database of prospectively registered 
systematic reviews in health and social care (Registration ID: CRD42020191196). 
Data Assessment 
A formal statistical analysis was not conducted as part of the systematic review due to 
overlapping data sets for studies using the same database (see Results). Moreover, there was a 




A total of 8,588 studies were identified from the search engines after deduplication. 
Study abstracts were screened, and 89 studies were identified for full text review. Fourteen 
studies met inclusion criteria and are included in the systematic review (Figure 1). General 
characteristics of the included studies are listed in Table 1. Of the 14 studies, five examined 
the Nationwide Inpatient Sample (NIS) database over different and overlapping time periods. 
Thirteen studies were conducted in the United States and one study was done in Canada 
(Table 1). A summary of a population description is included in each database (Table 3). The 
list of diagnosis codes used by each study is provided in the Supplement. 
Overall Incidence 
All included studies described an overall incidence of IE. Figure 2 illustrates 
contemporary trends of IE incidence per 100,000 people from the year 2000 through 2017. 
Data from four Olmsted County studies
22-25
 using the Rochester Epidemiology Project (REP) 





























































































2). There were a few studies which included yearly trends of IE incidence before 2000. 
However, the current systematic review was limited to contemporary trends of IE over the 
past two decades.  
Overall, there was great variability observed in trends of overall incidence of IE, with 
no appreciable increase noted over time (Figure 2). The study by Kadri 2019 described a 
much higher IE incidence compared to that of other investigations performed during the same 
time frame, and hence was plotted on a secondary axis in Figure 2.  
Patient Demographics 
 IE was predominately seen in older patients. The lowest mean age (59.1 years) 
recorded was by Thornhill  and the highest mean age (76.0 years) was reported by Bikdeli . 
The studies by Mendiratta  and Bikdeli  et al only included patients aged ≥65 years, which 
accounts for a comparatively higher mean age reported in both studies (76.0 and 79.4, 
respectively). IE was more common in men as reported by all but two studies (Thornhill  and 
Bikdeli ) (Table 1). 
Injection Drug Use  
 Five of 14 studies, from different study populations, reported trends of percentage 
changes in IE in PWID. Wong 2020 reported incidence numbers for IE in PWID, instead of 
percentages, as illustrated on the secondary axis of Figure 3. There has been a notable 
increase in percentage prevalence of opioid use and IDU among patients with IE as reported 
by individual studies (see Supplement). There were 3 studies that reported only the overall 
percentage prevalence of IDU in an IE cohort during their respective study periods. 
DeSimone  reported an overall PWID prevalence of 10% among patients with IE which did 





























































































of 16.6%, as a proportion of total IE cases while Tleyjeh  reported a PWID-IE prevalence of 
3% over a 30 year study period.  
Microbiology 
Nine studies detailed pathogens (Table 1). Seven studies reported S. aureus as the 
most common pathogen with VGS as the most common in 2 studies. The prevalence of 
enterococci was reported in 4 studies with the highest (22%) prevalence described by 
DeSimone  . Coagulase-negative staphylococci were reported as an exclusive entity by 5 
studies and  Correa and DeSimone et al. reported the highest (10%) prevalence. 
Outcomes 
The percentage of patients who required cardiac valvular surgery for IE was 
documented in seven studies (range: 6.4 – 16.0%). Other outcomes examined included 
inpatient, six-month and one-year mortality rates. Inpatient mortality was reported in seven 
studies, with rates ranging from 3.7% to 14.4%. Six-month mortality was described in three 
studies and rates were much higher, ranging from 26.7% to 31.8%. Four studies reported 
rates of one-year mortality, which was very consistent, ranging from 36.2% to 37.1% (Table 
1).  
DISCUSSION 
The overall incidence of IE has remained stable in North America in the years 2000-
2017, based on the findings of our systematic review.  This finding may be somewhat 
unanticipated as results from single- and multi-center investigations predominate in the 
literature and are subject to referral and other biases. Thus, our reliance on only population-





























































































IDU, perhaps, is a predisposing condition of IE in North America, particularly in the 
United States, that has garnered the most attention over the past ~20 years. The increase in 
prevalence of IDU among IE patients that was demonstrated in this review is not surprising, 
given the ongoing opioid epidemic in North America, which has resulted in an 11-fold 
increase in deaths related to opioid drug overdose between 2013 and 2019. The prevalence of 
IDU represents a major change in more traditional risk factors associated with the 
development of IE and has had a direct effect on the demographics of IE patients. Wong et 
al., for example, highlighted a marked increase in incidence of IE among persons aged 18–29 
years between 2007 and 2017, likely attributable to PWID. This population poses a sizable 
burden to the healthcare system in North America. Fleischauer et al highlighted that 42% of 
PWID with IE in North Carolina were either uninsured or on Medicaid, for example. The 
dramatic increase in PWID-IE cases seen in this state alone between 2010 and 2015 was 
striking, with resultant increases of 1,800 percent in hospital expenditures. Moreover, the 
patients affected were young to middle-aged adults, which represents a population subset that 
forms an essential part of a country’s economic workforce. Coupled with a concomitant 
burden of hepatitis C, HIV infection and risk of recurrent IE in patients who survive initial 
bouts of IE, there is a justified cause for concern as public health and other agencies involved 
in healthcare delivery devise strategies to reduce the tremendous burden of complications, 
including IE, due to the opioid epidemic.  
Because this burden has received considerable attention, and rightfully so, the 
assumption has been that IDU has resulted in an increase in IE incidence and impacted the 
epidemiology of IE throughout North America. Our systematic review, however, did not 
demonstrate an incidence increase which could be due to a phenomenon of “geographic 
heterogeneity” in regard to IDU and areas of the United States. Because of variability of rates 





























































































coupled with the recognition that population-based studies in North America included in this 
review have surveyed only specific portions of the entire population of either Canada or the 
United States, could explain, in part, the lack of increase in IE incidence. 
There has been variability of reported IE incidence among other global sites. For 
example, investigations from England have demonstrated a rising incidence of IE following a 
total restriction in AP for certain dental procedures has occurred, but a causal relationship 
between increasing incidence and AP restrictions was not established. Of note, the authors 
raised concerns regarding the inconsistent use of ICD coding and primary and secondary 
diagnoses that have been used to define IE cases in different studies which could have 
markedly influenced estimates of IE incidence. These factors were closely linked to the 
number of different ICD-9/10 codes used to identify IE cases, as reflected in incidence rates 
displayed in Figure 2. It is notable that all studies with an incidence in the 5-10 cases per 
100,000 range used a restricted number of ICD-9/10 codes (with either primary or a restricted 
number of primary/secondary diagnosis codes) (See Supplement) or Duke/modified Duke 
criteria. In contrast, studies with higher IE incidence rates used a much broader set of ICD-9 
and10 codes in both the primary and secondary position. Interestingly, Fawcett et al. reported 
that more than half of the cases that were coded using ICD-10 as IE in study centers were not, 
in fact, confirmed cases. For example, the code I38 from ICD-10, used in both Wong  and 
Kadri 9, had a PPV of less than 6%. They reported that sensitivity and positive predictive 
values (PPV) of ICD-9 codes were 70%. This is lower than measures reported in Toyoda  
(sensitivity 94%; PPV 94%) (Table 4). Moreover, there is a discrepancy in the use of 
surrogate codes for IE in PWID, since there are no specific ICD 9/10 codes for PWID, 
resulting in studies reporting varying data for hospitalization of patients for the same year 
using the same database . Furthermore, it is suggested that studies which use ICD-10 for 





























































































misclassifying more than half the patients, prompting questions regarding the accuracy of 
codes. This demonstrates a need for ICD codes to be standardized and validated with other 
records before conducting population-based studies.  
 ICD-9 codes were most often used in our shortlisted studies, since it was only after 
2015 that medical centers in North America fully adopted ICD-10 coding. However, there are 
several nuances that should be considered when using ICD-9 coding to determine incidence 
of IE. ICD-9 codes used until 2015 in the US were not confined to diagnosis codes; they also 
included many procedure codes – and procedure codes are more important than diagnosis 
codes for billing purposes. This is not the case with ICD-10 codes used in Europe since they 
only include diagnosis codes and other systems are used for coding when procedures have 
been performed. It most likely affects the way coders record information and different coding 
strategies adopted in Europe and the US for identifying IE cases, since healthcare systems in 
Europe converted to ICD-10 coding before the year 2000. This also suggests that data 
recorded after 2015 in North America may differ from those recorded before 2015. 
Another key aspect to consider is the large difference in incidence reported by Kadri 
2019 as compared to that by the remainder of studies. The authors examined the NIS 
database, which was used by 4 other studies included in this review. However, Kadri et al. 
observed an incidence range of 179 to 289 cases per 100,000, compared to 2.61 to 39.10 
cases per 100,000, reported in other studies. One possible reason for the prevailing difference 
is the large number of ICD codes (12 ICD-9 codes and 10 ICD-10 codes) used to identify 
patients. Kadri et al also reported a steep rise in IE incidence following 2010. Thus, it is 
tempting to speculate that a real increase in IE incidence may not have occurred due to use of 





























































































Bikdeli et al. also detected a high incidence of IE in their cohort as compared to that 
seen in other studies. This should have been expected since their cohort included Medicare 
patients and IE has been characteristically predominant among older individuals. 
Nevertheless, it was intriguing to note the vast disparity in incidence as determined by use of 
primary codes only versus use of both primary and secondary codes (Figure 2). This 
observation should be viewed with caution, however, as it highlights the high sensitivity and 
low specificity of secondary codes in incidence studies, and is most likely an overestimation 
of true IE incidence.  
Since population-based studies are the underpinnings of evidence to detect even the 
slightest of changes in incidence for an uncommon, yet life-threatening disease like IE, there 
is a need for standardization of study protocols and ICD code linkage and validation in order 
to ascertain a more generalizable and precise measurement of IE incidence across the world. 
In North America, different databases use a variety of combinations of standard codes to 
ascertain incidence of IE, which leads to a disparity in available evidence. Similar studies 
conducted in Europe that used more robust, standardized nationwide registries, have also 
fallen prey to pitfalls of coding issues. Therefore, the authors have proposed 
recommendations for conducting future incidence and epidemiologic studies of IE. (Table 5) 
Trends in the incidence of IE from 2000 to 2017 in North America are of importance 
in part because of the AHA guideline update in 2007 widely followed in both the US and 
Canada, where the population indicated for pre-operative AP was restricted to patients at 
highest risk of IE. The lack of increase in IE incidence demonstrated in our investigation 
following availability of the 2007 AHA guidelines is reassuring. Work from Mackie and 
colleagues deserves highlighting. It was based on data from Canada and they made a similar 
observation and reported a slight increase in IE hospitalizations in all age groups from 2002 





























































































following implementation of AHA guidelines. These data were not included in the systematic 
review, however, due to inability to segregate age groups of interest.  
Among causative pathogens, S. aureus was reported as the most common cause 
followed by VGS. The increase in S. aureus-related IE can be attributed to a multitude of 
factors, including increasing PWID and healthcare-associated procedures. The prevalence of 
VGS has been declining recently; Slipzcuk et al. reported a decrease in VGS prevalence from 
27.4% to 17.6% in IE patients over the past five decades in their systematic review. VGS 
coding deserves special comment as we address IE incidence due to this group of pathogens. 
Although there have been specific ICD-9/10 codes for many organisms, including S. aureus, 
no codes exist for VGS. Therefore, assigning infection due to VGS has been a process of 
elimination, by excluding other types of streptococci that harbour specific ICD-9/10 codes 
(e.g. ICD 10 code A49.1 for streptococcal infection at an unspecified site). This practice, 
coupled with use of “big data” studies, has resulted in estimates of VGS IE incidence that 
have been suboptimal or incorrect. Moreover, it is difficult to ascertain the impact of 2007 
AHA prevention guidelines on VGS IE incidence as the true number might be skewed due to 
factors that impact the recording of supplementary and secondary codes for VGS IE. In 
addition, because Enterococcus faecalis, a prevalent cause of IE in the elderly, was listed as 
“Streptococcus faecalis” in ICD-9 coding, in at least one survey this likely impacted the 
reported increase in “streptococcal” IE incidence.  
The need for surgical intervention in IE patients ranged from 6.4 to 16.0%. This in 
contrast to previously conducted studies that reported surgery in up to 25% to 50% of IE 
patients. Since most of these studies are not population-based and were conducted at surgical 






























































































The range of in-hospital mortality rates demonstrated in this review was lower as 
compared to that described in previous systematic reviews by Slipzcuk et al. (8 to 40%) and 
Tleyjeh et al (16 to 21%). Despite these relatively low in-hospital mortality rates, 1-year 
mortality persisted; just over 1 in 3 patients were dead by 1 year (36.2 to 37.1%, Table 1). 
A recently published systematic review compared incidence of IE before and after 
implementation of major guidelines changes for AP use and invasive procedures . In contrast 
to the number (n=14) of North American studies included in our review, the Williams 
publication included only eight investigations that focused on trend comparisons in “before 
and after” guideline changes. Moreover, we used time plots to observe changes in IE 
incidence over the past 20 years, irrespective of changes in international guidelines. This was 
done to assess factors other than AP use that might have impacted the incidence of IE. 
Williams et al. included three studies that were excluded from our review because the cohorts 
in those studies included pediatric IE cases . Furthermore, we included more contemporary 
studies that extended to May 2020. It is also important to highlight that there are considerable 
demographic differences between North American and European populations with IE that 
were combined in the Williams’ review, which deserve separate analysis; Europe has not 
been affected to the same degree by the opioid epidemic seen in North America, for example.  
Limitations  
 Despite the thoroughness of the current systematic review, there were certain 
limitations that deserve mention. Only studies with patients aged 18 years and older were 
included, which resulted in the exclusion of a small number of robust population-based 
investigations. There were two studies that included patients age ≥ 65 and one that included 
patients limited to ages 18-64. These studies were included as the authors of this review 





























































































IE is different than that seen in adults and bacterial pathogens that cause IE are similar among 
all adult age groups, albeit with a higher prevalence for enterococcal species in older patients. 
Only one study from Canada fit the study’s inclusion criteria, which might not be an adequate 
representation of IE incidence in that country. There was also great heterogeneity in the 
variety of ICD codes used in each included investigation, and a lack of availability of trends 
data for causal pathogens and risk factors prohibited us from conducting a meta-regression 
analysis. Lastly, trends for VGS IE were not available, which would have been of interest to 
accurately assess the impact of antibiotic prophylaxis guidelines regarding dental procedures 
on incidence of VGS IE over the past two decades. The addition of a secondary code specific 




 Based on findings of this systematic review, the incidence of IE in North America has 
remained stable between 2000-2017, despite increasing rates of IDU-related IE. A 
standardized approach to the use of ICD coding to optimally define IE incidence is needed in 
subsequent population-based investigations. In addition, sustained efforts are needed to 
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Table 1: Clinical features of patient populations in included studies. 

















































































aureus - 33.0,  
Enterococcus 































































































































































































































NR 42.1 NR NR NR 
Canada 




















 NIS – National Inpatient Sample  





























































































CoNS – coagulase-negative staphylococci 
GNB – gram-negative bacilli 
REP – Rochester Epidemiology Project  
NR – Not reported 
 
*The genus and species of the pathogens have been listed as presented in the individual 
studies. Since the pathogens were grouped differently in each study, it was not possible for us 










































































































Tleyjeh 2005 Adequate Adequate Adequate Adequate 
Mendiratta 
2009 Adequate Adequate Inadequate 
Adequate 
Correa 2010 Adequate Adequate Adequate Adequate 
Garg 2012 Adequate Adequate Inadequate Adequate 
Bikdeli 2013 Adequate Adequate Inadequate Adequate 
DeSimone 
2015 Adequate Adequate Adequate 
Adequate 
Toyoda 2017 Adequate Adequate Inadequate Adequate 
Thornhill 2018 Adequate Adequate Inadequate Adequate 
Alkhouli 2019 Adequate Adequate Inadequate Adequate 
Kadri 2019 Adequate Adequate Inadequate Adequate 
Moreyra 2019 Adequate Adequate Inadequate Adequate 
McCarthy 2020 Adequate Adequate Inadequate Adequate 
Mori 2020 Adequate Adequate Inadequate Adequate 





































































































A collaboration of clinics, hospitals and other medical facilities in 
27 counties in Minnesota and Wisconsin. 
National Inpatient 
Sample (NIS) 
Constructed annually by including 100% of the discharges from 
20% of US hospitals. 
Medicare Inpatient 
Standard Analytical Files 
Medicare is the primary health insurer of 97% of the US 
population 65 years and older. 
Statewide Planning and 
Research Cooperative 
System database 
Prospectively collects data on every hospital discharge, 
ambulatory surgery, and emergency department visit in the state 
of New York. 
Office of Statewide 
Health Planning and 
Development database  
Prospectively collects data on every hospital discharge, 
ambulatory surgery, and emergency department visit in the state 
of California. 
Myocardial Infarction 
Data Acquisition System 
(MIDAS) 
Covers all discharges with the diagnosis of acute myocardial 
infarction in New Jersey, based on the New Jersey hospital 
discharge data system. 
Premier Healthcare 
Database (PHD) 
An electronic healthcare database from approximately 800 private 
and academic hospitals, representing approximately 20% of US 
inpatient discharges. 
Truven Database Includes those covered by employer-sponsored private health 
insurance involving more than 260 employers and 40 health 
plans, with 240 million covered lives and 32 billion service 
records. 
IBM MarketScan Includes diagnosis and procedure codes for 26 million persons 
who enrolled in approximately 350 employer-sponsored 































































































Table 4: Summary of studies that performed ICD code validation 
Study Codes/criteria used Comment Validity 
Toyoda 2017 
 






Sensitivity 94%  
Specificity 99%  
PPV 94%  
Thornhill 2018 
 
ICD 9. Primary and 
secondary 
Record linkage 









using ICD codes 
Sensitivity 94% 
Specificity 99%  
PPV 94% 
Mori 2020 ICD 9 and 10. Primary 
and secondary.  
 
Record linkage 
using ICD codes 
 
Sensitivity 94%  
Specificity 99%  































































































Table 5: Recommendations for conducting incidence and epidemiologic studies of infective 
endocarditis. 
 
1. Population-based studies should be designed and conducted to minimize the risk of 
bias and ensure the adequacy of case ascertainment, disease definition, sampling 
techniques and population definition. 
2. Studies should report a separate analysis of adult (18 years and older) and pediatric 
patients, as the clinical aspects of IE are markedly different for the two groups.  
3. Investigators should consider the date for implementation of ICD 10 codes, i.e. 2015 
in the USA, when reporting trend data. 
4. All studies should report separately ICD-10 code I33 in the primary position in order 
to facilitate comparison of rates across populations.  
5. Designate a code for PWID as a modification for ICD 11, to prevent use of non-
specific surrogate codes. 
6. Designate codes for VGS-IE as a modification for ICD 11, as a common pathogen 
associated with IE. 
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